Rheinmetall AG is expanding its footprint in the defense medical technology sector. The Düsseldorf-based group, through its subsidiary Rheinmetall Mobile Systeme GmbH, has secured a NATO contract from Denmark for the supply of five mobile field hospitals. The order, valued in the mid-double-digit million-euro range, is scheduled for the end of 2025. This move underscores a deliberate corporate strategy to develop military medical infrastructure as a complementary growth area alongside its core business of traditional weapon systems.
Order Details and Technical Specifications
The Danish Ministry of Defence has ordered two distinct types of field hospitals. The contract includes three units of the Role 2B (Basic) category and two of the more advanced Role 2E (Enhanced) type. Designed for rapid deployment, the Basic variant is fully container-based and mounted directly onto trucks, enabling quick relocation and operational readiness.
Both hospital systems are engineered for temporary autonomous operation. They come equipped with independent power, water, and oxygen supplies, along with integrated military medical treatment facilities. Rheinmetall emphasized that the medical equipment was selected in close consultation with the Danish customer, ensuring compatibility with devices already established within the Danish medical service. Delivery of all five field hospitals is expected to be completed within a two-year timeframe.
A Burgeoning Order Book Amid Broader Portfolio Showcase
This Danish contract arrives amidst a series of recent order announcements from the defense contractor. In February, the company reported a NATO call-off order for 120mm tank ammunition worth approximately €200 million. It also secured a Swedish order for the Seasnake-30 system, with an initial volume of €63 million.
Should investors sell immediately? Or is it worth buying Rheinmetall?
The group’s broadening technological portfolio was further displayed at the Enforce Tac 2026 exhibition in Nuremberg. Among the innovations presented was the Fuchs JAGM vehicle, which Rheinmetall claims is the world’s first platform to feature 24 vertically launched AGM-179 JAGM missiles from Lockheed Martin.
Management has set ambitious financial targets for 2026, aiming for defense-related sales of €15 to €16 billion with an operating margin between 18% and 20%. The company’s total order backlog is projected to rise to approximately €135 billion by the end of the current year.
Upcoming Financial Disclosure and Long-Term Ambitions
Investor attention now turns to Rheinmetall’s upcoming full-year results. The company is set to release its complete financial figures for 2025, along with a detailed outlook for the current business year, on March 11.
Market analysts anticipate a substantial expansion of the order book, driven significantly by German defense contracts placed in the first half of the year. Looking further ahead, Rheinmetall’s long-term strategy envisages achieving global sales of €40 billion by 2030. The ongoing diversification into sectors like military medical infrastructure may play a more substantial role in reaching this goal than previously estimated.
Ad
Rheinmetall Stock: Buy or Sell?! New Rheinmetall Analysis from February 27 delivers the answer:
The latest Rheinmetall figures speak for themselves: Urgent action needed for Rheinmetall investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 27.
Rheinmetall: Buy or sell? Read more here...
